论文部分内容阅读
目的对低分子肝素联合泼尼松治疗小儿肾病综合征的临床疗效进行观察分析。方法 70例小儿肾病综合征患儿,随机分为对照组和观察组,各35例。对照组患儿使用泼尼松进行治疗,观察组在泼尼松治疗的基础上联合低分子肝素进行治疗,对两组临床疗效进行观察比较。结果对照组总有效率为71.4%,观察组总有效率为94.3%;比较差异具有统计学意义(P<0.05)。观察组各项实验室检查结果均优于对照组(P<0.05)。观察组凝血酶原时间为(14.31±1.43)s、活化部分凝血活酶时间为(31.95±3.64)s,对照组分别为(14.36±1.45)、(32.05±3.64)s;观察组凝血指标优于对照组,但差异无统计学意义(P>0.05)。结论低分子肝素联合泼尼松治疗小儿肾病综合征临床疗效显著,安全性高,值得临床推广应用。
Objective To observe and analyze the clinical effect of low molecular weight heparin and prednisone on children with nephrotic syndrome. Methods 70 cases of children with nephrotic syndrome were randomly divided into control group and observation group, 35 cases each. The control group of children treated with prednisone, the observation group on the basis of prednisone combined with low molecular weight heparin for treatment, the clinical efficacy of the two groups were observed and compared. Results The total effective rate of the control group was 71.4%, the total effective rate of the observation group was 94.3%; the difference was statistically significant (P <0.05). The observation group of laboratory tests were better than the control group (P <0.05). The prothrombin time in the observation group was (14.31 ± 1.43) s, the activation partial thromboplastin time was (31.95 ± 3.64) s in the control group, and (14.36 ± 1.45) and (32.05 ± 3.64) s in the control group In the control group, but the difference was not statistically significant (P> 0.05). Conclusion Low molecular weight heparin combined with prednisone treatment of children with nephrotic syndrome significant clinical effect, high safety, deserved clinical application.